Bioverativ Inc (BIVV) Shares Bought by Teachers Advisors LLC

Teachers Advisors LLC raised its stake in Bioverativ Inc (NASDAQ:BIVV) by 12.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 130,950 shares of the biotechnology company’s stock after purchasing an additional 14,435 shares during the quarter. Teachers Advisors LLC owned about 0.12% of Bioverativ worth $7,061,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Bioverativ by 16.9% during the 4th quarter. BlackRock Inc. now owns 10,845,635 shares of the biotechnology company’s stock valued at $584,795,000 after acquiring an additional 1,567,638 shares in the last quarter. Old Mutual Global Investors UK Ltd. lifted its holdings in shares of Bioverativ by 47.8% during the 4th quarter. Old Mutual Global Investors UK Ltd. now owns 2,507,002 shares of the biotechnology company’s stock valued at $135,177,000 after acquiring an additional 810,364 shares in the last quarter. Jackson Square Partners LLC lifted its holdings in shares of Bioverativ by 21.1% during the 4th quarter. Jackson Square Partners LLC now owns 2,107,110 shares of the biotechnology company’s stock valued at $113,615,000 after acquiring an additional 366,503 shares in the last quarter. OppenheimerFunds Inc. lifted its holdings in shares of Bioverativ by 147.1% during the 4th quarter. OppenheimerFunds Inc. now owns 1,434,200 shares of the biotechnology company’s stock valued at $77,332,000 after acquiring an additional 853,853 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Bioverativ by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 1,382,422 shares of the biotechnology company’s stock valued at $74,541,000 after acquiring an additional 137,792 shares in the last quarter. Institutional investors own 97.18% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several equities analysts recently weighed in on BIVV shares. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 target price on the stock in a report on Monday, January 8th. Raymond James lowered shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd. Jefferies Group lifted their target price on shares of Bioverativ to $79.00 and gave the company a “buy” rating in a report on Thursday, January 18th. Morgan Stanley raised shares of Bioverativ from an “underweight” rating to an “equal weight” rating in a research note on Tuesday, January 23rd. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a $65.00 price target on shares of Bioverativ in a research note on Thursday, January 18th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $64.70.

Bioverativ stock opened at $104.98 on Friday. Bioverativ Inc has a 12-month low of $48.14 and a 12-month high of $105.01.

Bioverativ (NASDAQ:BIVV) last released its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.01. The firm had revenue of $328.70 million for the quarter, compared to the consensus estimate of $325.89 million. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. equities research analysts forecast that Bioverativ Inc will post 3.82 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Bioverativ Inc (BIVV) Shares Bought by Teachers Advisors LLC” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/04/22/teachers-advisors-llc-has-7-06-million-position-in-bioverativ-inc-bivv.html.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply